Dulaglutide
Trulicity (dulaglutide) is a once-weekly injectable medication used to improve blood sugar control in adults with type 2 diabetes. It belongs to the GLP-1 receptor agonist class and works by mimicking the action of the incretin hormone GLP-1, which stimulates insulin release and reduces glucagon secretion in a glucose-dependent manner. This medication is typically used as an adjunct to diet and exercise for patients who need better glycemic control.
Trulicity is a weekly injectable GLP-1 receptor agonist used to treat type 2 diabetes by helping the pancreas produce more insulin in response to blood sugar levels.
Key facts at a glance
- RxNorm
- 1551296
- Generic
- Trulicity
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Trulicity is indicated for use in adults with type 2 diabetes to improve glycemic control. It is used as part of a comprehensive diabetes management plan that includes diet, exercise, and potentially other glucose-lowering medications. Some formulations may also be indicated for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease.
Trulicity is a GLP-1 receptor agonist that mimics the action of the naturally occurring hormone glucagon-like peptide-1 (GLP-1). It works by binding to GLP-1 receptors, which stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon secretion from alpha cells, slows gastric emptying to reduce postprandial glucose spikes, and promotes feelings of fullness to potentially reduce food intake.
Trulicity is administered as a once-weekly subcutaneous injection. Common side effects may include nausea, diarrhea, vomiting, and abdominal pain. It should not be used in patients with a personal or family history of medullary thyroid carcinoma or in those with Multiple Endocrine Neoplasia syndrome type 2. Trulicity is not a substitute for insulin and is not indicated for use in patients with type 1 diabetes or diabetic ketoacidosis. Patients should be monitored for signs of pancreatitis and should follow proper injection technique as instructed by their healthcare provider.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy